Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HRGN'
s FCF Margin % Range Over the Past 10 Years
Min: -11414.63 Med: -3937.97 Max: -452.77
Current: -452.77
During the past 13 years, the highest FCF Margin % of Harvard Apparatus Regenerative Technology was -452.77%. The lowest was -11414.63%. And the median was -3937.97%.
HRGN's FCF Margin % is ranked worse than 98.87% of 1951
companies
in the Consumer Packaged Goods industry
Industry Median: 2.04
vs HRGN: -452.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Apparatus Regenerative Technology FCF Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Harvard Apparatus Regenerative Technology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Apparatus Regenerative Technology (HRGN) has a FCF Margin % of -414.60% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Harvard Apparatus Regenerative Technology and its competitors. According to the industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1929 out of 1951 companies in the Consumer Packaged Goods industry, placing it in the top 98.9%.
Is Harvard Apparatus Regenerative Technology's FCF Margin % too high?
Harvard Apparatus Regenerative Technology's current FCF Margin % is -414.60%. Based on the distribution chart, Harvard Apparatus Regenerative Technology ranks #1929 out of 1951 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's FCF Margin % compare to JVA and BRLS?
According to the Consumer Packaged Goods industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1929 out of 1951 companies for FCF Margin %. This places Harvard Apparatus Regenerative Technology in the lower half of its industry. The industry median FCF Margin % is 2.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Consumer Packaged Goods company?
The median FCF Margin % among Consumer Packaged Goods companies is 2.04, based on 1,951 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Harvard Apparatus Regenerative Technology and its competitors. For the Consumer Packaged Goods industry, the median FCF Margin % is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Apparatus Regenerative Technology's current FCF Margin % is -414.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Harvard Apparatus Regenerative Technology (HRGN) has a current FCF Margin % of -414.60%. The current FCF Margin % is -414.60%. Harvard Apparatus Regenerative Technology's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current FCF Margin % is -414.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
14GF Score
Get the complete analysis for HRGN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRGN has been successfully added to your 
